Get the Stockscreener App
0.93
7.92%
-0.08
After Hours:
.93
NanoViricides Inc stock is traded at $0.93, with a volume of 208.39K.
It is down -7.92% in the last 24 hours and down -17.70% over the past month.
NanoViricides, Inc., a nano-biopharmaceutical company, discovers, develops, and commercializes therapeutics for the treatment of viral infections. The company is developing anti-influenza drug candidates at pre-clinical and advanced pre-clinical stage, which include two FluCide drugs, such as NV-INF-2, an oral anti-influenza drug and NV-INF-1, an injectable anti-influenza drug for H7N9, Bird Flu H5N1, and other Highly Pathogenic Influenzas; and HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate that could provide functional cure for HIV/AIDS. It is also developing HerpeCide, a skin cream or gel formulation for the treatment of oral and genital herpes virus infections; and eye drops against viral infections of the external eye, as well as involved in the other research programs against Rabies virus, Ebola, and Marburg viruses. NanoViricides, Inc. was founded in 2005 and is based in Shelton, Connecticut.
See More
Previous Close:
$1.01
Open:
$0.99
24h Volume:
208.39K
Relative Volume:
0.66
Market Cap:
$20.06M
Revenue:
-
Net Income/Loss:
$-8.29M
P/E Ratio:
-1.3286
EPS:
-0.7
Net Cash Flow:
$-6.47M
1W Performance:
+9.41%
1M Performance:
-17.70%
6M Performance:
-39.61%
1Y Performance:
-33.57%
1-Day Range:
$0.93
$1.05
1-Week Range:
$0.88
$1.05
52-Week Range:
$0.85
$2.2299
NanoViricides Inc Stock (NNVC) Company Profile
Name
NanoViricides Inc
Sector
Industry
Phone
203-937-6137
Address
1 Controls Drive, Shelton, CT
Compare NNVC vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNVC
NanoViricides Inc
|
0.93 | 21.78M | 0 | -8.29M | -6.47M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
NanoViricides Inc Stock (NNVC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Initiated | Alliance Global Partners | Buy |
| Feb-11-15 | Initiated | Midtown Partners | Strong Buy |
NanoViricides Inc Stock (NNVC) Latest News
Small cap wrap: BioVie, VivoPower, NanoViricides, Aftermath Silver... - Proactive financial news
NanoViricides seeks FDA orphan status for MPox drug - Proactive financial news
MPox Orphan Drug Designation Application Filed for NV-387, Declares NanoViricides - Bitget
New Mpox drug candidate NV-387 chases FDA orphan status - Stock Titan
NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX) - Barchart.com
Small cap wrap: Medicus Pharma, 1911 Gold, NanoViricides, Nextech3D.ai, NextSource Materials… - Proactive Investors
Measles cases surge as NanoViricides seeks orphan status for NV-387 - Stock Titan
NanoViricides seeks orphan drug status with US FDA for measles treatment - Proactive financial news
NanoViricides President Dr. Diwan Interviewed by Mission Matters’ Adam Torres - USA Today
Trading Recap: Is NanoViricides Inc part of any ETFJuly 2025 Drop Watch & Real-Time Buy Signal Alerts - baoquankhu1.vn
CEO Change: Is NanoViricides Inc undervalued by DCF analysisWeekly Stock Recap & Safe Entry Zone Identification - baoquankhu1.vn
NanoViricides President Discusses Broad-Spectrum Antiviral Platform and Upcoming Phase II Trial for MPox Treatment - citybuzz -
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza WaveNV-387 is Effective Against H3N2 - Enterprise News
NanoViricides President Dr. Diwan Interviewed by Mission Matters' Adam Torres - accessnewswire.com
Can NanoViricides Inc. continue delivering strong returnsJuly 2025 Momentum & Weekly Watchlist for Consistent Profits - mfd.ru
Can NanoViricides Inc continue delivering strong returnsQuarterly Growth Report & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
NanoViricides, Inc. Has Filed its Quarterly ReportSubsequent Raise Has Fortified Fiscal Position - Hattiesburg American
NanoViricides to Present at the 3rd Annual DealFlow Discovery Conference - chronicle-tribune.com
NanoViricides Announces Closing of $6 Million Registered Direct Offering and Concurrent Private Placement Priced at the Market Close - hattiesburgamerican.com
NanoViricides Has Signed a Master Services Agreement with OnlyOrphansCote Regarding Orphan Drug Strategy of NV-387 for Treatment of MPox, Smallpox, and Measles - Hattiesburg American
ETF Watch: Should I hold or sell NanoViricides Inc nowJuly 2025 Chart Watch & AI Powered Market Entry Ideas - baoquankhu1.vn
Aug Momentum: Is NanoViricides Inc forming a bullish divergenceTrade Analysis Summary & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Support Test: Should I invest in NanoViricides Inc before earningsJuly 2025 PostEarnings & Free Fast Gain Swing Trade Alerts - baoquankhu1.vn
Jobs Data: How much upside does NanoViricides Inc have2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
NanoViricides Highlights Need for Broad-Spectrum Antivirals During Severe Influenza Season - citybuzz -
NanoViricides highlights need for broad-spectrum antivirals amid severe flu season - Proactive financial news
San Gabriel Valley Tribune - FinancialContent
Options Flow: Will NanoViricides Inc. stock continue dividend increases2025 Winners & Losers & Short-Term Swing Trade Alerts - Bộ Nội Vụ
Market Recap: Can NanoViricides Inc NV3P stock sustain institutional flowsInflation Watch & Stock Portfolio Risk Control - Bộ Nội Vụ
After-Hours Rally: Zentalis, LifeMD, And NanoViricides Among Top Gainers - Nasdaq
Published on: 2026-01-10 19:47:32 - ulpravda.ru
Volume Summary: Will NanoViricides Inc NV3P stock outperform small cap peersJuly 2025 Chart Watch & Reliable Breakout Forecasts - moha.gov.vn
NanoViricides Has Received Approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ACOREP of the Democratic Republic of Congo - patriotledger.com
Can NanoViricides Inc. stock outperform in 2025 bull marketJuly 2025 Weekly Recap & Reliable Price Action Trade Plans - Улправда
Can NanoViricides Inc. stock hit record highs againPortfolio Update Summary & Expert Curated Trade Setup Alerts - Улправда
NanoViricides Inc Stock (NNVC) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):